RFP | March 3, 2014
U.S. Department of Health and Human Services, National Institutes of Health, National Institute on Drug Abuse announces the availability of funding for implementation of the Prevention and Treatment of Substance Using Populations With or at Risk for Hepatitis C Virus (HCV) (R21) Exploratory/Developmental Research Grant. The purpose of this grant is to conduct the initial development of a clinical trial or research project focused on prevention and treatment of HCV for at-risk substance using populations, including those infected with or at risk for HIV. The R21 mechanism supports investigation of novel scientific ideas or new model systems . . .